pentoxifylline has been researched along with Myelodysplastic Syndromes in 8 studies
Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tumor necrosis factor-alpha (TNF-alpha) levels were measured in the serum (sTNF-alpha) or bone marrow (BM) biopsies of 43 patients with myelodysplastic syndromes (MDS) who subsequently received therapy with a combination of pentoxifylline and ciprofloxacin (PC) with or without dexamethasone (PCD)." | 5.08 | Tumor necrosis factor-alpha levels decrease with anticytokine therapy in patients with myelodysplastic syndromes. ( Dar, S; Qawi, H; Raza, A; Reza, S; Shetty, V, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Erikci, AA | 1 |
| Ozturk, A | 1 |
| Karagoz, B | 1 |
| Bilgi, O | 1 |
| Turken, O | 1 |
| Top, C | 1 |
| Kandemir, EG | 1 |
| Kim, MK | 1 |
| Lee, JL | 1 |
| Cho, HS | 1 |
| Bae, SH | 1 |
| Ryoo, HM | 1 |
| Lee, KH | 1 |
| Hyun, MS | 1 |
| Nemunaitis, J | 1 |
| Rosenfeld, C | 1 |
| Getty, L | 1 |
| Boegel, F | 1 |
| Meyer, W | 1 |
| Jennings, LW | 1 |
| Zeigler, Z | 1 |
| Shadduck, R | 1 |
| Reza, S | 2 |
| Shetty, V | 2 |
| Dar, S | 2 |
| Qawi, H | 2 |
| Raza, A | 4 |
| Mundle, SD | 1 |
| Ali, A | 1 |
| Mativi, Y | 1 |
| Venugopal, P | 2 |
| Gregory, SA | 1 |
| Lisak, L | 1 |
| Andric, T | 1 |
| Andrews, C | 1 |
| Gezer, S | 1 |
| Gregory, S | 1 |
| Loew, J | 1 |
| Robin, E | 1 |
| Rifkin, S | 1 |
| Hsu, WT | 1 |
| Huang, RW | 1 |
| Novitzky, N | 1 |
| Mohamed, R | 1 |
| Finlayson, J | 1 |
| du Toit, C | 1 |
1 review available for pentoxifylline and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes.
Topics: Arthritis, Rheumatoid; Crohn Disease; Etanercept; Humans; Immunoglobulin G; Myelodysplastic Syndrome | 2000 |
3 trials available for pentoxifylline and Myelodysplastic Syndromes
| Article | Year |
|---|---|
The hematologic response to anti-apoptotic cytokine therapy: results of pentoxifylline, ciprofloxacin, and dexamethasone treatment for patients with myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Anti-Inflammatory Agents; Apoptosis; Ciprofloxacin; | 2006 |
Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome. A phase II trial.
Topics: Adult; Aged; Ciprofloxacin; Colony-Forming Units Assay; Drug Therapy, Combination; Female; Hematopoi | 1995 |
Tumor necrosis factor-alpha levels decrease with anticytokine therapy in patients with myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Biopsy; Ciprofloxacin; Dexamethasone; Drug Therapy, Combination; Female; He | 1998 |
4 other studies available for pentoxifylline and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Results of combination therapy with amifostine, pentoxifylline, ciprofloxacin and dexamethasone in patients with myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Ciprofloxacin; Dexamethason | 2008 |
Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes.
Topics: Apoptosis; Bone Marrow Cells; Caspase 1; Caspase 3; Caspases; Cell Separation; Cells, Cultured; HL-6 | 1999 |
Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Anorexia; Antineoplastic Combined Chemotherapy Protocols | 2000 |
Increased apoptosis of bone marrow cells and preserved proliferative capacity of selected progenitors predict for clinical response to anti-inflammatory therapy in myelodysplastic syndromes.
Topics: Anti-Inflammatory Agents; Antigens, CD34; Apoptosis; Blood Transfusion; Bone Marrow Cells; Cell Divi | 2000 |